Mirae Asset Global Investments Co., Ltd. Trevi Therapeutics, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $28 Billion
- Q2 2025
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,930 shares of TRVI stock, worth $41,658. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,930
Previous 2,902
35.42%
Holding current value
$41,658
Previous $18,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TRVI
# of Institutions
163Shares Held
110MCall Options Held
1.07MPut Options Held
425K-
Nea Management Company, LLC Timonium, MD13.2MShares$140 Million6.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$109 Million2.96% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$90.4 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.32MShares$56.4 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.49MShares$47.6 Million5.2% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $618M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...